| Detected | Trial | Change |
|---|---|---|
| 2026-08-15 | NCT05650749 GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma |
overall status: Recruiting → Enrolling by Invitation |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT05029336 | Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases | Systemic Lupus Erythematosus | Recruiting |
| NCT04276870 | Orphan Indications for CD19 Redirected Autologous T Cells | Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL | Recruiting |
| Phase 1/2 | |||
| NCT05674175 | Co-administration of CART22-65s and huCART19 for B-ALL | B-cell Acute Lymphoblastic Leukemia | Recruiting |
| NCT05480449 | Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for… | B Cell Acute Lymphoblastic Leukemia (B-ALL) | Recruiting |
| Phase 1 | |||
| NCT06934382 | Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or… | T-Cell Acute Lymphoblastic Leukemia/Lymphoma | Recruiting |
| NCT07464951 | CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia (AML) | Recruiting |
| NCT07007117 | PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma | Refractory Neuroblastoma | Active, Not Recruiting |
| NCT05650749 | GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma | Refractory Neuroblastoma | Enrolling by Invitation |